# PT-141 Side Effects Observed in Research Studies > PT-141 side effects from Phase 3 clinical trials: nausea 40%, flushing 20.3%, headache 11.3%, transient blood pressure elevation, and hyperpigmentation. Full safety profile from 3,500 subjects. ## PT-141 Side Effects Observed in Research Studies PT-141 side effects have been characterized in one of the largest clinical development programs for a sexual-dysfunction compound: approximately 3,500 subjects across 43 studies, including two Phase 3 randomized controlled trials and a 52-week open-label extension [9]. All data on this page reflects research subjects in published clinical trials. ## PT-141 Side Effects in Clinical Research In Phase 3 double-blind bremelanotide trials, the adverse-event rates were: nausea 40.0% (vs. 1.3% placebo), flushing 20.3% (vs. 0.3%), headache 11.3% (vs. 1.9%) [9]. These are the three most common adverse events and occurred at substantially higher rates than placebo. Nausea was the most common reason for study discontinuation. No deaths were reported across the 43-study clinical program. Serious adverse events were minimal. Drug interactions were clinically significant only with indomethacin (increased exposure) and naltrexone (modified plasma concentrations) [9]. Transient increases in blood pressure were documented across three doses (0.75, 1.25, 1.75 mg SC) in a 397-subject ambulatory blood pressure monitoring study [8]. At 1.75 mg, systolic blood pressure increased 3.1–3.2 mmHg versus placebo in the 0–4 hour post-dose window (p=0.006–0.027), with peak increases typically lasting less than 15 minutes. Heart rate reductions of -4.6 to -4.7 bpm were also observed at 1.75 mg [8]. The drug is contraindicated in subjects with uncontrolled hypertension or known cardiovascular disease. ## Nausea as the Primary Adverse Event in PT-141 Trials Nausea was the most common adverse event in Phase 3 bremelanotide trials, reported in approximately 40% of subjects — versus 1.3% in the placebo arm — and was the leading cause of discontinuation [9]. The mechanism is consistent with MC4R agonism; MC4R is expressed in both hypothalamic arousal circuits and emetic pathways. Strategies studied in the clinical program to reduce nausea-related discontinuation included patient selection (excluding subjects with a history of nausea) and co-administration of ondansetron (an antiemetic). Both approaches reduced discontinuation rates in protocol-specific analyses [9]. ## Skin Pigmentation Effects of PT-141 Focal hyperpigmentation — darkening of skin on the face, gums, or breast tissue — is a recognized adverse event linked to MC1R activation. At therapeutic doses and label-compliant frequency, hyperpigmentation is rare [9]. In research protocols using consecutive daily dosing for 16 days, over one-third of subjects developed hyperpigmentation [9]. Post-market bremelanotide data and FDA labeling document this adverse event; the label recommends discontinuation if hyperpigmentation develops. Pigmentation changes may be persistent after discontinuation. ## Safety Profile of PT-141 in Clinical Trials The clinical trial safety database for bremelanotide includes approximately 3,500 subjects across 43 studies. The overall safety profile is characterized as: a high rate of nausea (~40%) that is the primary driver of discontinuation; transient blood pressure elevation that resolves within 12 hours; and hyperpigmentation risk that is frequency-dependent rather than dose-dependent [9, 8, 14]. No deaths were reported. No clinically significant cardiac arrhythmias were identified. A Phase 1 study of bremelanotide co-administered with ethanol (0.6 g/kg) found no clinically significant pharmacokinetic interaction and no drug-related serious adverse events [20]. ## Is PT-141 Safe Based on Available Research? The safety signal from the bremelanotide clinical program is one of manageable adverse events rather than serious harm. Major concerns are nausea (~40%), transient blood pressure elevation (requiring contraindication in uncontrolled hypertension), and hyperpigmentation at high-frequency dosing [9, 8]. At label-compliant dosing frequency (maximum 8 doses per month), the 52-week open-label extension data showed sustained tolerability with no new safety signals through 76 weeks total exposure [14]. ## References [8] White WB, et al. Ambulatory blood pressure monitoring for bremelanotide. Journal of Hypertension. 2017. https://pubmed.ncbi.nlm.nih.gov/27977473/ [9] Clayton AH, et al. Safety Profile of Bremelanotide. Journal of Women's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35147466/ [14] Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide. Obstetrics and Gynecology. 2019. https://pubmed.ncbi.nlm.nih.gov/31599847/ [20] Jordan R, et al. Phase I Study of Bremelanotide Coadministered With Ethanol. Journal of Clinical Pharmacology. 2017. https://pubmed.ncbi.nlm.nih.gov/28189361/ --- Coin-operated reading room for the bremelanotide literature — every trial catalogued, no clinical service rendered.